Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Retinal Degeneration

Interventions

BIOLOGICAL

tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)

Single subretinal injection of vector suspension; up to 3x10e12 vector particles

Trial Locations (1)

Moorfields Eye Hospital NHS Foundation Trust, London

All Listed Sponsors

collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

collaborator

Targeted Genetics Corporation

INDUSTRY

lead

University College, London

OTHER

NCT00643747 - Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis | Biotech Hunter | Biotech Hunter